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ABSTRACT
Background and objective: Mediastinal lymphad-
enopathy (MLN) in human immunodeficiency virus
(HIV) infection has a wide spectrum of aetiologies with
different prognoses and treatments. The decision to
pursue ahistopathological diagnosis represents a clini-
cal challenge as patients present with non-specific
symptoms. This study aimed to determine the aetiol-
ogy and predictive factors of MLN in a cohort of HIV-
infected patients in the combination antiretroviral
therapy (cART) era.
Methods: Single-centre retrospective cohort study of
217 consecutive HIV-infected patients who underwent
computed tomography (CT) of the chest between
January 2004 and December 2009. Fifty-two patients
were identified to haveMLN (>10 mm in short axis). CT
imageswere re-reviewedby an independent radiologist
blinded to the clinical information. Final diagnoses of
MLN were obtained from clinical records. Multivariate
analysis was performed to identify predictors of aetiol-
ogy of MLN.
Results: Seventeen patients (33%) had a diagnosis of
malignancy.Consolidation onCTwas associatedwith a
reduced likelihood of malignancy odds ratio (OR) 0.03
(95% confidence interval 0.002–0.422), and larger
lymph nodes were associated with an increase in the
odds of malignancy (OR 2.89; 95% confidence interval
1.24–6.71). CD4 count was found not to be a predictor
of aetiology of MLN.
Conclusions: In the era of combination cART, oppor-
tunistic infections and malignancy remain to be the
frequent causes of MLN in HIV-positive patients, but
the prevalence of non-HIV related malignancy has
increased compared with previous studies. Although
certain findings are predictors of non-malignant
disease, pathological diagnosis of MLN in HIV-positive
patients should be pursued whenever possible.
Key words: antiretroviral agent, computed tomography scan,
human immunodeficiency virus, lymph node, mediastinum.
Abbreviations: cART, combination antiretroviral therapy; CT,
computed tomography; HIV, human immunodeficiency virus;
IRIS, immune reconstitution inflammatory syndrome; MLN,
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INTRODUCTION
Combination antiretroviral therapy (cART) has
changed the landscape of human immunodeficiency
virus (HIV) infection, with significant declines in
associated morbidity and mortality. Prior to the
advent of cART, pulmonary disorders were among the
most common complications of HIV infection. They
were predominantly infectious diseases and were
linked to unfavourable outcomes.1–3 With the intro-
duction of cART, the epidemiology of pulmonary
complications emerging in successfully treated HIV-
infected patients has shifted. The spectrum includes
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SUMMARY AT A GLANCE
We evaluated radiological, laboratory and clinical
data of HIV patients with MLN in the era of
combination ART. Opportunistic infections and
malignancy remain frequent causes of MLN in
HIV-positive patients, but the prevalence of non-
HIV-related malignancy has increased compared
with previous studies, emphasizing the need for
histological diagnosis.
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fewer infections, fewer acquired immune deficiency
syndrome-defining cancers and an increased fre-
quency of chronic obstructive pulmonary disease4,5
and non-acquired immune deficiency syndrome-
defining cancers, particularly lung cancer.6,7
Mediastinal lymphadenopathy (MLN) has been
previously reported to occur in 35–40% of patients
infected with HIV.8,9 The broad range of aetiologies
and the non-specific clinical presentation represent a
diagnostic challenge.8,10
The utility of chest computed tomography (CT) for
assessing pulmonary disease in HIV infection has
been widely explored and is a key initial radiological
investigation.9 It allows characterization of non-
specific radiographic patterns and detection of occult
lung disease as well as assessment of the mediasti-
num and airways.11 However, the role of chest CT in
the aetiological diagnosis ofMLN in patients withHIV
infection is not well characterized. In addition, previ-
ously published series were conducted prior to the era
of cART.8,9 Although nodal biopsy is ultimately the
gold standard for clarifying the aetiology of MLN,12–14
it is important to identify whether clinical, laboratory
or radiological predictors can be used to guide or
obviate the need for invasive sampling. Such variables
may, in fact, be useful in predicting a specific diagno-
sis and thus help developing a tailored management
strategy in this group of patients.
To our knowledge, no study to date has focused on
the mode of diagnosis of MLN in HIV-infected
patients in the era of cART. In this study, we aimed to
identify the causes of MLN in HIV-infected patients
presenting to a specialist unit and to characterize
their mode of diagnosis and follow-up.We also aimed
to identify clinical and radiological predictors of MLN
aetiology in this patient group.
METHODS
Participants, setting and data collection
We conducted a retrospective analytical cohort study
of HIV-positive patients who underwent CT scanning
of the chest at University College London Hospitals
between 1 January 2004 and 31 December 2009 for
investigation of respiratory symptoms. For patients
with more than one scan, only their initial CT scan
was included for analysis. Data were collected from
January 2010 through January 2012. A total of 271 con-
secutive patients were identified. All patients were
known to be HIV-1 antibody positive at the time of
scanning. Clinical indications for CT were collected
for all 271 patients (Fig. 1).
CT scan of the thorax was performed using an elec-
tron beam scanner (Siemens SOMATOM Sensation
Multislice CT scanner, Siemens Healthcare AG,
Erlangen, Germany). CT images were reviewed in the
standard axial plane, with coronal reconstructions, on
both mediastinal (soft tissue) and lung window set-
tings. CT slice thickness varied between 1 and 3 mm.
The scanning protocols adopted were: standard arte-
rial phase chest CT (36-s post-intravenous contrast),
high-resolution CT and CT pulmonary angiogram
depending on the clinical indication at the time.
All original CT reports were reviewed by the same
observer (J.A.), and MLN was initially identified in 56
patients. These CT images were then evaluated inde-
pendently by one thoracic radiologist (M.T.) who was
blinded to all clinical data, except for HIV status. The
conventional CT cut-off for significant intrathoracic
lymphadenopathy of 10 mm in short-axis15 was
employed.
The radiological features were recorded using the
Fleischner Society Glossary of Terms for Thoracic
Imaging.16 Location and size of MLN, presence
of necrosis and of extrathoracic lymphadenopathy
were recorded. The lung parenchyma was evaluated
for presence of consolidation, ground-glass opaci-
fication, cavity or cyst formation, lung nodules and
airways disease (indicated by emphysema, bronchial
wall thickening or bronchiectasis).
Baseline demographic, laboratory and clinical data
were collected from electronic medical records and
included age, sex, HIV risk factors, ethnicity, most
recent CD4 cell count and duration of receipt of cART.
All 52 patients were followed up for at least 12months
after the initial assessment.
Diagnostic criteria
Final diagnoses of MLN were based on positive
pathology or microbiology and clinical and radiologi-
cal follow-up of at least 6 months duration. Defini-
tions for particular conditions can be found in
Appendix S1 in the online supporting information.
Statistical analysis
For descriptive analysis, 52 patients with HIV infec-
tion andMLNonCT scan of the thorax were included.
For univariate and multivariate analysis of CT find-
ings, CD4 cell count and duration of cART as predic-
tors of specific aetiology, we restricted our analysis to
patients with a definitive final diagnosis (n = 48). Due
to the sample size and to allow correct modelling,
we restricted our analysis to groups of aetiologies
accounting for at least a third of patients.
CD4 cell counts were converted into categorical
variables and stratified into three groups >500, 200–
500, and <200 cells/mm3 in accordance with the 2008
Center for Disease Control and Prevention Revised
Classification System for HIV infection.17 Times
between CT and start of cART were converted into
dichotomous variables (before and after CT).
For univariate analysis, odds ratios (OR) and 95%
confidence intervals were calculated to assess the risk
for having cancer (lymphoma, lung cancer, other
malignancy). A two-sided P-value ≤0.05 was used to
define statistical significance.
For multivariate analysis, we calculated adjusted
OR for radiological and laboratory findings associated
with malignancy by using logistic regression with
backward elimination (likelihood ratios). Variables
were chosen based on statistical significance (P < 0.1)
in univariate analysis or previously published
evidence.8,9
Statistical analysis was performed using the soft-
ware SPSS version 18 (IBM Corporation, Armonk, NY,
USA) and Stata Version 10 (Statcorp, Houston, TX,
USA).
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The observational nature of the study meant that
ethical approval was not required, as determined
by the United Kingdom National Research Ethics
Service. The design, analysis and report of this study
conform to the Standard of Reporting Diagnostic
Accuracy statement.18
RESULTS
Two hundred seventy-one consecutive patients
underwent chest CT in the study period. All patients
were HIV-1 antibody-positive. Significant (>10 mm)
intrathoracic lymphadenopathy was present in 52
patients (19%). A specific diagnosis was made in 48
cases (92%). Of the four patients without a diagnosis,
three were lost to follow-up, and one patient had
persistent calcified MLN attributed to previous
mycobacterial infection.
Clinical indication for CT
Abnormal chest X-ray (21.8%), weight loss plus night
sweats and/or fever (10.3%), and shortness of breath
(5.9%) were the three commonest clinical indications
for CT (Table S1 in the online supporting information
for full details).
Demographic, clinical and
pathological characteristics
The median age (interquartile range) of the popula-
tion with intrathoracic lymphadenopathy was 40
(35–44) years, and their demographic characteristics
are summarized in Table 1.
Twenty-four (46%) patients were receiving cART, 19
were cART-naïve, and cART status was unclear for
nine (17%) patients. There were no relevant differ-
ences in demographic characteristics between the
cART/cART-naïve patients. The majority (61%) had
Figure 1 Flowchart of human immuno-
deficiency virus (HIV)-positive patients
undergoing computed tomography (CT)
chest diagnosed with intrathoracic lym-
phadenopathy. COPD, chronic obstruc-
tive pulmonary disease; IRIS, immune
reconstitution inflammation syndrome;
MLN, mediastinal lymphadenopathy;
NSCLC, non-small-cell lung cancer;
TB, tuberculosis.
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started cART at least 1 year prior to undergoing CT
thorax. Seventeen (90%) of the 19 cART-naïve patients
had started cART following CT.
Twenty-seven patients had a CD4 lymphocyte
count below 250 cells × 106/L at the time of CT (see
Table 2).
Spectrum of disease
The aetiologies of MLN are summarized in Table 2.
Tuberculosis was the single most common diagnosis
accounting for nine (17%) cases. In total, 17 patients
(33%) had a diagnosis of malignancy with lymphoma
accounting for eight (15%) cases. Two cases of
immune reconstitution inflammation syndrome
(IRIS) were identified.
In patients on cART, lymphoma (17%) and bacterial
pneumonia (13%) were the commonest diagnoses
with tuberculosis accounting for 8% of cases only. In
cART-naïve patients, tuberculosis (26%) was the com-
monest diagnosis, with lymphoma and bacterial
pneumonia accounting for 11% of cases each.
Mode of diagnosis
Final diagnoses were established by histopathology in
24 cases (50%), histopathology with microbiology in
five cases (10%), microbiology in seven (15%), and
clinical and/or radiological follow-up in 11 patients
(23%). Flexible bronchoscopy was done in nine cases
(17%).
Histopathological sampling was performed using
ultrasound-guided aspiration of peripheral lymph
nodes (ultrasound-guided fine needle aspiration)
(n = 19), mediastinoscopy (n = 3) or endobronchial
ultrasound-guided transbronchial needle aspiration
(n = 3).
CT findings
Using the Mountain–Dresler lymph node map,19
the most frequently involved mediastinal node sta-
tions were 2, 4, 7 and 8 (see Table 3). Lymph node
size varied from 1 to 7 cm with a median size
(interquartile range) of 1.55 cm (1.28–2.55).
The radiological features observed for each diagno-
sis are shown in Table S2 in the online supporting
information. Extrathoracic lymphadenopathy, lung
nodules and consolidation were the three most
common radiological findings and were observed
in 58% (n = 30), 54% (n = 28) and 37% (n = 19) of
patients, respectively. Extrathoracic lymphadenopa-
thy was a feature in six cases (75%) of lymphoma and
all cases of Kaposi’s sarcoma.
Clinical and radiographic predictors
In the logistic regression model for predicting a
diagnosis of malignancy, the following covariates
were included: age, ethnicity, HIV risk factor, absolute
CD4 count, parenchymal CT findings, presence
of extrathoracic lymphadenopathy, lymph node
maximum size and presence of necrotic lymph nodes.
In the univariate analysis, increased size of lymph
nodes appeared to be associated with an increased
risk of malignancy, whereas lung consolidation on
CT appeared to be associated with non-malignant
disease.
The multivariate analysis confirmed that the pres-
ence of consolidation on CT scan significantly
reduced the OR of malignancy in the MLN (OR 0.03,
95% confidence interval 0.002–0.422; P = 0.009). It
also confirmed that larger lymph nodes were more
likely to be malignant, with an increase of 1 cm in
short axis resulting in a 2.89 increase in the odds
of malignancy (95% confidence interval 1.24–6.71;
P = 0.014). Age, ethnicity, HIV risk factor, absolute
CD4 count, extrathoracic lymphadenopathy and
presence of necrotic lymphnodeswere not associated
with malignancy (Table 4).
DISCUSSION
This is the first study to assess the aetiology andmode
of diagnosis of HIV-infected patients with MLN in the
era of combination ART. Important findings have
been made that impact diagnosis and management.
Significant MLN was a common finding (19%) in
HIV-infected patients undergoing chest CT for assess-
ment of respiratory symptoms. Malignancy was a fre-
quent diagnosis, accounting for a third of cases (33%)
with non-HIV-related malignancies representing a
significant proportion of neoplasms (29%). IRIS was
identified for the first time as an aetiology of MLN.
Radiographic findings that may be useful predictors
of the aetiology of MLN were identified. Finally, MLN
sampling in this population is often necessary and
can be successfully and safely accomplished by
either endoscopic ultrasound-fine needle aspiration
or endobronchial ultrasound-guided transbronchial
needle aspiration.
Two other previously published studies addressed
the significance of MLN in HIV-infected patients;8,10
Table 1 Demographic characteristics of the study
population
Variable Number (%)
Age, median years (IQR) 40 (35–44)
Sex
Male 46 (88.5)
Female 6 (11.5)
Ethnicity
White 32 (61.5)
African Caribbean 12 (23.1)
Asian 2 (3.8)
Other 6 (11.5)
HIV risk factor†
MSM 28 (53.8)
Heterosexual 20 (38.5)
Bisexual 1 (1.9)
Vertical transmission 1 (1.9)
Intravenous drug use 5 (9.6)
† One heterosexual patient was infected through vertical trans-
mission; one MSM patient and one heterosexual patient were
intravenous drug users.
IQR, interquartile range; MSM, men who have sex with men.
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however, both were undertaken in the pre-ART era.
The frequency of MLN in our study (20%) is compa-
rable with the series by Jasmer et al. (35%).8 In both
series tuberculosis, bacterial pneumonia and lym-
phoma were the three most common diagnosis,
whereas mycobacterial disease and lymphoma
accounted for the majority of cases in the Fishman
and Sagar series.10 However, some differences can be
observed in the spectrum of disease. Compared with
Jasmer et al., our series shows an important decline in
the diagnosis of bacterial pneumonia (21% vs 10%)
and a marked increase in the number of non-HIV
related malignancies (3% vs 11%).
In our series, we also describe two cases of IRIS,
which were not identified by Jasmer et al. To our
knowledge, this is the first time IRIS is reported as
aetiology ofMLN inHIV-infected patients. Although it
has been associated with a range of opportunistic
infections, mycobacteria are the infections most
commonly implicated in IRIS.20 In our series, one of
the IRIS cases was associated with Mycobacterium
avium complex infection. The patient had a baseline
CD4 count of 70 cells × 106/L and presentedwith fever
and lymphadenitis within 1 month of starting combi-
nation ART. This is in line with the typical presenta-
tion of Mycobacterium avium complex IRIS.21 The
other patient with IRIS had been diagnosed with
cryptococcal meningitis the year before, and cART
was started at that stage.
The observed differences can have several explana-
tions. First, and perhaps more importantly, the study
periods were different with the Jasmer et al. series
reporting findings when cART was not available. In
fact, when stratified by cART status, the spectrum of
disease of the cART-naïve group was similar to that
observed by Jasmer et al. Our findings are also con-
sistent with the results from several recent
studies5,22–24 that have shown a change in the overall
spectrum of pulmonary disease in patients with HIV
infection with the use of cART. In fact, data from two
major longitudinal studies22,24 have demonstrated a
reduction in the rates of bacterial pneumonia and the
emergence of IRIS associatedwith antiretroviral treat-
ment. Other studies have demonstrated that the pro-
portion of non-HIV-related cancers has increased
significantly with the use of cART.25,26 Differences
between study populations, particularly ethnicity
Table 2 Aetiologies of MLN and CD4 count at time of diagnosis
CD4 lymphocyte count (cells × 106/L)†
Diagnosis <200 200–500 >500 Unknown Total n (%)
Tuberculosis 7 1 1 0 9 (17)
Non-tuberculous mycobacteria 1 1 1 0 3 (6)
PCP 1 1 0 0 2 (4)
Bacterial pneumonia 1 3 1 0 5 (10)
Other fungal infections§ 0 2 1 0 3 (6)
Lymphoma 2 3 1 2 8 (13.3)
Other malignancy‡ 1 1 2 1 5 (10)
Kaposi sarcoma 1 1 2 0 4 (8)
Castleman’s disease 0 1 0 0 1 (2)
IRIS 2 0 0 0 2 (4)
Other¶ 2 3 1 0 6 (11)
Unknown 4 4 (8)
Total 18 17 10 7 52
† CD4 groups according to CDC surveillance case definition for HIV.17
‡ Three patients with non-small cell lung cancer (one poorly differentiated non-small cell lung cancer, one anaplastic large cell
carcinoma and one squamous cell lung cancer), one patient with prostate cancer and one patient with metastatic poorly differentiated
carcinoma.
§ One patient with Aspergillosis, one patient with Cryptococcus, one patient with Candida.
¶ One patient with pulmonary oedema, one patient with sepsis, one patient with endocarditis, one patient with decompensated
chronic liver disease, one patient with sarcoidosis and one patient with infective exacerbation of chronic obstructive pulmonary disease.
CDC, Center for Disease Control and Prevention; HIV, human immunodeficiency virus; IRIS, immune reconstitution inflammatory
syndrome; MLN, mediastinal lymphadenopathy; PCP, Pneumocystis jirovecii pneumonia.
Table 3 Distribution of enlarged mediastinal lymph
nodes by station19
LN station
Number of
patients (n)
1 19
2 33
3 27
4 30
5 19
6 15
7 30
8 30
9 6
10 28
11 8
LN, lymph node.
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(our population was predominantly White (61.5%),
whereas in Jasmer et al., White and African American
ethnic groups accounted for 43% and 41% of cases)
and HIV risk factors (intravenous drug use 9.6% vs
30%), may also explain the variation in the results.
Previous studies established necrotic lymph nodes
for mycobacterial disease, airways disease for bacte-
rial pneumonia and absence of pulmonary nodules
for lymphoma as radiological predictors for those
aetiologies.8 In our series, multivariate analysis dem-
onstrated that the presence of consolidation (OR
0.03, P = 0.009) is an independent predictor for
having a diagnosis of non-malignant disease,
whereas larger lymph nodes increase the likelihood
(OR 2.89, P = 0.014) of malignancy. The results dem-
onstrate that the high frequency of MLN and the
wide spectrum of disease pose important diagnostic
challenges. The high prevalence of malignancy in this
setting also emphasizes the need for a pathological
diagnosis where possible. In our study, 68% of histo-
logical samples were obtained by ultrasound-guided
aspiration of peripheral lymph nodes, underlining
the importance of a thorough physical exam. For
MLN sampling, mediastinoscopy was performed
as frequently as endobronchial ultrasound-guided
transbronchial needle aspiration. This may owe to
the limited availability of endobronchial ultrasound-
guided transbronchial needle aspiration throughout
the first years covered by our study. Recent studies
have demonstrated that endobronchial ultrasound-
guided transbronchial needle aspiration can obviate
the need for mediastinoscopy in patients with
MLN.14,27
Our study has a number of limitations. Data were
obtained retrospectively from electronic records
review. However, we attempted to enhance the valid-
ity of the results by independent blinded review of the
chest CT scans with prospective recording of findings.
Due to the retrospective design, there were no stand-
ardized criteria for having a CT scan of the chest and
so it is difficult to exclude some selection bias.
However, our study is consistent with previous
reports in regards to incidence of MLN and main
diagnoses.8,9 Finally, this is a single-centre study with
a relatively small sample size, and therefore, the
results may not be generalizable, as significant dis-
crepancies in demographics, access to care, mode of
transmission, and availability of cART are common
among the HIV-infected population.
In the era of cART, opportunistic infections remain
frequent causes of MLN in HIV-positive patients, but
malignancy now may have a higher prevalence.
Although certain findings are predictors of non-
malignant disease, pathological diagnosis of MLN in
HIV-positive patients should be pursued whenever
possible.
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